In comparison, in a comprehensive molecular classification study involving 300 patients with GC, FGFR2 amplification was identified in 1.2% of MSS/TP53-intact subtype tumors, 3.0% of MSS/TP53-mutant subtype tumors, and 4.9% of mesenchymal-subtype tumors [3]. Here, TP53 is linked to gastric cancer.